Therapy News and Research

RSS

Seven week Summer Treatment Program benefits children with ADHD

Recently, 35 children with ADHD completed the Cincinnati Children's Summer Treatment Program (STP), a seven week program providing intensive behavioral interventions within a fun-filled camp setting.

5 Aug 2016

Researchers describe structure of Alzheimer fibrils at atomic resolution

Elongated fibres (fibrils) of the beta-amyloid protein form the typical senile plaque present in the brains of patients with Alzheimer's disease.

5 Aug 2016

Triple therapy approach helps Type 1 diabetes patients improve blood sugar control, lose weight

A combination of three medications—dapagliflozin, liraglutide and insulin—helped people with Type 1 diabetes improve blood sugar control and lose weight, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Aug 2016

Research shows alcohol abuse drug inhibits ocular conjunctival scarring in mouse model

New research from University College London, Moorfields Eye Hospital and Duke University School of Medicine has identified a gene that drives scarring, together with a rapidly translatable therapy, for the UK's most common cause of blinding conjunctivitis.

4 Aug 2016

Review highlights role of N-acetylcysteine in clinical management of COPD

Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death of United States and is associated with a significant number of hospital admissions per year among patients.

4 Aug 2016

Researchers develop method to kill cancer cells using nanoparticles and lasers

Cancer treatments based on laser irridation of tiny nanoparticles that are injected directly into the cancer tumor are working and can destroy the cancer from within.

4 Aug 2016

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach means some patients could delay taking highly toxic non-curative anticancer drugs that come with substantial side effects

4 Aug 2016

Research could help develop better therapies for new subtype of adenocarcinoma patients

Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease.

4 Aug 2016

Combinations of FDA-approved drugs may prevent vision loss linked to retinal degeneration

Combinations of Food and Drug Administration-approved drugs protect against the loss of cells required for vision in a mouse model of blinding retinal diseases.

4 Aug 2016

Research could provide new insights into finding cure for chronic infections

New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma.

4 Aug 2016

Rice University bioengineer receives NIH grant to study use of AAV-based therapy to combat ovarian cancer

Rice University bioengineer Junghae Suh has been awarded a prestigious R01 grant by the National Institutes of Health to research the use of viral gene therapy to fight ovarian cancer.

3 Aug 2016

Neurologists identify cause of immune-mediated neuropathies

Würzburg neurologists have discovered an antibody that is involved in triggering certain forms of neuropathies. This discovery also allowed them to show a way to treat these diseases successfully.

3 Aug 2016

Study shows link between inflammatory biomarkers and prevalence of CAD in HIV-infected men

A cardiac imaging study led by Hossein Bahrami, MD, PhD, assistant professor of cardiovascular medicine at the Keck School of Medicine of the University of Southern California, along with investigators from Johns Hopkins University and five other institutions, showed a correlation between higher inflammatory biomarkers and an increased prevalence of coronary artery disease (CAD) in men infected with human immunodeficiency virus (HIV).

3 Aug 2016

Priory Group opens Wellbeing Centre in Greater Manchester to help young people tackle stress

The Priory Group, the leading provider of mental healthcare in the UK, most commonly known for treating celebrities with addictions, has opened its first Wellbeing Centre in Cheadle, Great Manchester.

3 Aug 2016

Advances in head and neck cancer treatments: an interview with Prof. Argiris

Patients with head and neck cancer usually present with locally advanced disease and often require more than one type of treatment, which may include surgery, radiotherapy, and chemotherapy.

3 Aug 2016

Study shows diabetes drug ineffective in improving condition of patients with advanced heart failure

In an attempt to correct defects in the energy generation that contribute to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure.

2 Aug 2016

UTA researchers find how changing estrogen levels make women more vulnerable to cocaine addiction

Researchers at The University of Texas at Arlington are studying how fluctuating estrogen levels make females increasingly sensitive to the rewarding effects of cocaine and ultimately, vulnerable to cocaine addiction.

2 Aug 2016

Scientists develop model using transformed stem cells to accelerate screening of drugs for rare cancers

Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.

2 Aug 2016

Combination therapy shows no better benefits than placebo for patients with knee osteoarthritis

Chondroitin sulfate (CS) plus glucosamine sulfate (GS) was no better than placebo for reducing pain and function impairment in a multicenter, randomized, double-blinded, placebo-controlled study of 164 patients with knee osteoarthritis.

2 Aug 2016

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability of Selecta’s novel immune tolerance platform.

2 Aug 2016

Therapy News and Research

Seven week Summer Treatment Program benefits children with ADHD

Researchers describe structure of Alzheimer fibrils at atomic resolution

Triple therapy approach helps Type 1 diabetes patients improve blood sugar control, lose weight

Research shows alcohol abuse drug inhibits ocular conjunctival scarring in mouse model

Review highlights role of N-acetylcysteine in clinical management of COPD

Researchers develop method to kill cancer cells using nanoparticles and lasers

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Research could help develop better therapies for new subtype of adenocarcinoma patients

Combinations of FDA-approved drugs may prevent vision loss linked to retinal degeneration

Research could provide new insights into finding cure for chronic infections

Rice University bioengineer receives NIH grant to study use of AAV-based therapy to combat ovarian cancer

Neurologists identify cause of immune-mediated neuropathies

Study shows link between inflammatory biomarkers and prevalence of CAD in HIV-infected men

Priory Group opens Wellbeing Centre in Greater Manchester to help young people tackle stress

Advances in head and neck cancer treatments: an interview with Prof. Argiris

Study shows diabetes drug ineffective in improving condition of patients with advanced heart failure

UTA researchers find how changing estrogen levels make women more vulnerable to cocaine addiction

Scientists develop model using transformed stem cells to accelerate screening of drugs for rare cancers

Combination therapy shows no better benefits than placebo for patients with knee osteoarthritis

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News